<document xmlns="http://cnx.rice.edu/cnxml">
  <title>Epilepsy and Anticonvulsant Drugs </title>
  <metadata xmlns:md="http://cnx.rice.edu/mdml">
    <md:title>Introduction to Epilepsy and Anticonvulsant Drugs</md:title>
    <md:content-id>m00263</md:content-id>
    <md:uuid>cffc99f3-0673-4dcd-8651-3608209fcb2c</md:uuid>
  </metadata>
<content>
<section class="learning-objectives" id="sect-00001">
<title>Learning Outcomes</title>
<para id="para-00001">By the end of this section, you should be able to:</para>
<list id="list-00001">
<item>Describe the pathophysiology of epilepsy.</item>
<item>Identify the clinical manifestations related to epilepsy.</item>
<item>Identify the etiology and diagnostic studies related to epilepsy.</item>
<item>Identify the characteristics of drugs used to treat epilepsy.</item>
<item>Explain the indications, action, adverse reactions, and interactions of drugs used to treat epilepsy.</item>
<item>Describe nursing implications of drugs used to treat epilepsy.</item>
<item>Explain the client education related to drugs used to treat epilepsy.</item>
</list>
</section>
<section id="sect-00003">
<title>Overview of Epilepsy and Seizures</title>
<para id="para-00002">Seizures are a sudden and temporary disturbance in the electrical activity of the brain that can cause changes in behavior, movement, or consciousness. <term id="term-00001">Epilepsy</term>, on the other hand, is a neurological disorder characterized by recurrent seizures. In epilepsy, the seizures are typically unprovoked and can occur spontaneously without any apparent trigger. Epilepsy is a condition that affects approximately 3.4 million people in the United States, and it can have a significant impact on an individual’s quality of life (Centers for Disease Control and Prevention, 2020a, 2020c).</para>
<section id="sect-00004">
<title>Etiology</title>
<para id="para-00003">Seizures can have various causes such as fever, head injury, brain infection, drug or alcohol withdrawal or overdose, electrolyte imbalances, and metabolic disorders. Seizures may also result from brain tumors or masses, stroke, or other neurological conditions. Sometimes the cause of a seizure cannot be identified—a condition called an <term id="term-00002">idiopathic seizure</term> (Centers for Disease Control and Prevention, 2020b, 2020c).</para>
<para id="para-00004">Epilepsy, on the other hand, is a long-term neurological condition thought to be linked to abnormalities in the structure and function of the brain, which can be present at birth or develop later in life due to various factors such as brain injury, tumor, or stroke. Genetic factors may also play a role in the development of epilepsy. Understanding the underlying cause of epilepsy is important for effective diagnosis and treatment of the condition (Centers for Disease Control and Prevention, 2020a, 2020c).</para>
</section>
<section id="sect-00005">
<title>Pathophysiology</title>
<para id="para-00005">A <term id="term-00003">seizure</term> occurs when there is a sudden and abnormal burst of electrical activity in the brain. This activity can disrupt normal brain function and lead to a variety of symptoms, such as <term id="term-00004">convulsions</term>, loss of consciousness, and sensory or motor disturbances (Centers for Disease Control and Prevention, 2020a, 2020c).</para>
<para id="para-00006">Epilepsy is a chronic neurological disorder in which recurrent, unprovoked seizures occur. The underlying pathophysiology of epilepsy involves a disruption in the normal balance of excitatory and inhibitory activity in the brain. This imbalance can be due to structural or functional abnormalities in the brain, genetics, or changes in neurotransmitter activity. The abnormal electrical activity in the brain that occurs during an epileptic seizure is thought to be caused by a sudden release of excitatory neurotransmitters or a sudden decrease in inhibitory neurotransmitters (Centers for Disease Control and Prevention, 2020a, 2020c).</para>
</section>
<section id="sect-00006">
<title>Diagnostic Testing</title>
<para id="para-00007">Diagnosis of seizures or epilepsy is multifaceted. The health care provider will obtain a thorough history and perform a neurological examination. The health care provider may order one or more of the following diagnostic tests to identify seizures or rule out other causes or structural abnormalities that could be contributing to the seizure diagnosis:</para>
<list list-type="bulleted" id="list-00002">
<item><term id="term-00005">Electroencephalogram (EEG)</term>
<list list-type="bulleted" id="list-00003">
<item>An EEG is a test that measures changes in the brain’s electrical patterns that relate to seizures or other neurological conditions. Small metal electrodes are attached to the scalp, and the electrical impulses of the brain appear as wavy lines on the EEG recording.</item>
</list></item>
<item><term id="term-00006">Computed tomography (CT) scan</term>
<list list-type="bulleted" id="list-00004">
<item>A CT scan is a noninvasive imaging procedure that uses x-rays to produce horizontal and axial images of the brain.</item>
</list></item>
<item><term id="term-00007">Magnetic resonance imaging (MRI)</term>
<list list-type="bulleted" id="list-00005">
<item>An MRI of the brain is a painless imaging procedure that uses large magnetic radio waves to produce clear images of the structures inside the skull.</item>
</list>
</item>
<item><term id="term-00008">Positron emission tomography (PET) scan</term>
<list list-type="bulleted" id="list-00006">
<item>A PET scan is an imaging procedure that uses a radioactive tracer substance to detect disease or injury in the brain.</item>
</list></item>
</list>
</section>
<section id="sect-00007">
<title>Clinical Manifestations</title>
<para id="para-00008">Clinical manifestations of seizures can vary depending on the type of seizure a person is experiencing. There are several types of seizures, but they are generally classified into two groups: <term id="term-00009">generalized seizures</term> and <term id="term-00010">focal seizures</term>.</para>
<para id="para-00009">Generalized seizures involve abnormal activity in both sides of the brain from the beginning of the seizure. The two types of generalized seizures are <term id="term-00011">absence seizures</term> and <term id="term-00012">tonic-clonic seizures</term> (Centers for Disease Control and Prevention, 2020a, 2020c).</para>
<list list-type="bulleted" id="list-00007">
<item>Absence seizures, also known as <term id="term-00013">petit mal seizures</term>, cause rapid blinking or a few seconds of staring into space.</item>
<item>Tonic-clonic seizures involve both tonic (muscle stiffness) and clonic (muscle jerking) phases and are commonly known as <term id="term-00014">grand mal seizures</term>.</item>
</list>
<para id="para-00010">Focal seizures, also known as <term id="term-00015">partial seizures</term>, begin in a specific area of the brain and can cause a wide range of symptoms depending on the area of the brain that is affected. There are three types of focal seizures: <term id="term-00016">simple focal seizures</term>, <term id="term-00017">complex focal seizures</term>, and <term id="term-00018">secondary generalized seizures</term> (Centers for Disease Control and Prevention, 2020a, 2020c).</para>
<list list-type="bulleted" id="list-00008">
<item>Simple focal seizures affect a small part of the brain and cause twitching movements or a change in sensation, such as an odd taste or smell.</item>
<item>Complex focal seizures make a person confused or dazed. The person will be unresponsive to questions or directions for up to a few minutes.</item>
<item>Secondary generalized seizures begin in one part of the brain but then spread to the other side. The person first has a focal seizure, followed by a generalized seizure.</item>
</list>
<note class="link-to-learning" id="note-00001">
  <title>Epilepsy and Seizures</title>
<media alt="atoms_isotopes">
<iframe width="560" height="315" src="https://openstax.org/r/epilepsy"/>
</media>
<para id="para-00011">Alila Medical Media presents an educational video on epilepsy and seizures.</para>
</note>
</section>
</section>
<section id="sect-00008">
<title>Drugs Used to Treat Epilepsy</title>
<para id="para-00012">Drugs that are used to treat epilepsy and seizures are generally termed <term id="term-00019">anticonvulsant drugs</term>. Anticonvulsant drugs are used to either control acute seizures or as maintenance to prevent seizures from occurring. Other drug classifications, such as some central nervous system depressants and mood stabilizers, have also been shown to be effective in the treatment of seizures and epilepsy. This section of the chapter will cover commonly prescribed classes of drugs used to treat seizures and epilepsy: hydantoins, barbiturates, succinates, benzodiazipines, iminostilbenes, valproates, pyrrolidine derivatives, and other anticonvulsants.</para>
<para id="para-00013">Importantly, numerous medications utilized for epilepsy treatment may interact with other drugs. Therefore, the nurse should thoroughly evaluate all the medications a client is currently taking, including over-the-counter products and herbal supplements. If any questions or concerns arise, the nurse should consult with a more knowledgeable health care provider or pharmacist to ensure the client’s safety and prevent the occurrence of potential drug interactions.</para>
<section id="sect-00009">
<title>Hydantoins</title>
<para id="para-00014"><term class="no-emphasis" id="term-00020">Hydantoins</term> are a class of anticonvulsant drugs that are used to prevent or control seizures. Hydantoins can reduce the occurrence and severity of seizures by stabilizing the neuronal membrane in the brain. Some commonly prescribed hydantoins include phenytoin and fosphenytoin. Although hydantoins can be effective in controlling seizures, they can have significant adverse effects, including dizziness, drowsiness, and coordination problems. Long-term use can lead to complications such as osteoporosis and <term id="term-00021">gingival hyperplasia</term> (gum overgrowth). Contraindications of hydantoins include hypersensitivity to hydantoins or substances they contain, sinus bradycardia or heart block, and liver disease. They should be used cautiously in people who are pregnant or breastfeeding as they can be harmful to the fetus or baby (Gupta &amp; Tripp, 2022).</para>
<para id="para-00015">Therapeutic drug monitoring, which may be necessary for optimal treatment outcomes, is an essential task for nurses. Careful review of serum blood levels—trough levels and peak levels—is crucial to make appropriate dosing adjustments. Trough levels indicate the lowest concentration of the drug in the blood and are typically measured just before the client’s next scheduled dose. As a valuable indicator of the clinically effective range of serum levels, trough levels help confirm client compliance.</para>
<para id="para-00016">On the other hand, peak levels are indicative of an individual’s threshold for potential dose-related adverse effects and are measured at the peak concentration time. The goal is to achieve a therapeutic effect without clinical signs of toxicity, which is more likely to occur when serum total concentrations range between 10 and 20 mcg/mL. Therefore, close monitoring of serum blood levels, including both trough and peak levels, enables health care providers to optimize dosing, maximize therapeutic benefits, and minimize the risk of adverse effects.</para>
<para id="para-00017"><term class="no-emphasis" id="term-00022">Phenytoin</term> (<term class="no-emphasis" id="term-00066">Dilantin</term>) is the most prescribed hydantoin. <link target-id="table-00001" document="m00263"/> is a drug prototype table for hydantoins featuring phenytoin. It lists drug class, mechanism of action, adult and <term class="no-emphasis" id="term-00023">pediatric dosage</term>s, indications, therapeutic effects, drug and food interactions, adverse effects, and contraindications.</para>
<table class="vertically-tight" id="table-00001">
<tgroup cols="2">
<colspec colnum="1" colname="c1" colwidth="1*"/>
<colspec colnum="2" colname="c2" colwidth="1*"/>
<tbody>
<row>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Drug Class</span></emphasis><newline/>
Anticonvulsant<newline count="2"/>
<emphasis effect="bold"><span class="blue-text">Mechanism of Action</span></emphasis><newline/>
Decreases abnormal electrical activity in the brain through a voltage-dependent blockade of membrane sodium channels that are responsible for action potential
</entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Drug Dosage</span></emphasis><newline/>
Individualized based on disease process.<newline count="2"/>
<emphasis effect="italics">Adults:</emphasis> Initial dose of 100 mg extended-release capsule by mouth 3 times daily.<newline/>
Upward titration with a maximum of 2 capsules 3 times daily.<newline count="2"/>
Serum blood level determinations may be necessary for optimal dosing adjustments.<newline count="2"/>
<emphasis effect="italics">Children:</emphasis> Initial dose of 5 mg/kg/day in 2 or 3 equally divided doses, with subsequent dosage individualized to a maximum of 300 mg daily.<newline count="2"/>
A recommended daily maintenance dosage is usually 4 to 8 mg/kg.<newline/>
Children over 6 years old and adolescents may require the minimum adult dose (300 mg/day).
</entry>
</row>
<row>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Indications</span></emphasis><newline/>
To treat tonic-clonic and psychomotor seizures<newline/>
To prevent and treat seizures that occur during neurosurgery<newline count="2"/>
<emphasis effect="bold"><span class="blue-text">Therapeutic Effects</span></emphasis><newline/>
Reduce seizure activity<newline/>
</entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Drug Interactions</span></emphasis><newline/>
Azoles<newline/>
Antineoplastic agents<newline/>
Delavirdine<newline/>
Neuromuscular blocking agents<newline/>
Warfarin<newline/>
Calcium channel blockers<newline/>
Antilipemic agents<newline/>
Antacids<newline count="2"/>
<emphasis effect="bold"><span class="blue-text">Food Interactions</span></emphasis><newline/>
No significant interactions<newline/>
</entry>
</row>
<row>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Adverse Effects</span></emphasis><newline/>
Nystagmus<newline/>
Ataxia<newline/>
Slurred speech<newline/>
Decreased coordination<newline/>
Somnolence<newline/>
Mental confusion
</entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Contraindications</span></emphasis><newline/>
Hypersensitivity<newline/>
Prior history of acute hepatotoxicity attributed to phenytoin<newline/>
Bradycardia or heart block<newline count="2"/>
Caution:<newline/>
Monitor closely clients who have depression because this drug can increase suicidal thoughts or behavior<newline count="2"/>
Caution also advised for using this drug during pregnancy because it may cause potential harm to the fetus<newline/>
</entry>
</row>
</tbody>
</tgroup>
<caption><emphasis effect="bold">Drug Prototype: Phenytoin</emphasis> (source: https://dailymed.nlm.nih.gov/dailymed/)</caption>
</table>
</section>
<section id="sect-00010">
<title>Barbiturates</title>
<para id="para-00018"><term class="no-emphasis" id="term-00024">Barbiturates</term> are a class of drugs that act as central nervous system depressants, leading to sedation and relaxation. Barbiturates work by enhancing the actions of <term id="term-00025">gamma aminobutyric acid (GABA)</term>, the neurotransmitter that slows down brain activity. GABA is boosted by barbiturates, making them useful as sedatives, hypnotics, and anticonvulsants. Notably, barbiturates have a high risk of addiction, tolerance, and overdose, so their use has declined in favor of safer alternatives. Common adverse effects of barbiturates include dyspnea, confusion, bradycardia, dizziness, drowsiness, nausea, and vomiting. This class of drugs is contraindicated in people with hypersensitivity to barbiturates or their components, in those with hepatic insufficiency, and in those with respiratory disorders (Skibiski &amp; Abdijadid, 2022).</para>
<para id="para-00019"><term class="no-emphasis" id="term-00026">Phenobarbital</term> is the most used barbiturate for the treatment of seizures. Therapeutic drug monitoring is required. Phenobarbital is also a strong CYP inducer and will decrease the concentration of many other drugs. <link target-id="table-00002" document="m00263"/> is a drug prototype table for barbiturates featuring phenobarbital. It lists drug class, mechanism of action, adult and <term class="no-emphasis" id="term-00027">pediatric dosages</term>, indications, therapeutic effects, drug and food interactions, adverse effects, and contraindications.</para>
<table class="vertically-tight" id="table-00002">
<tgroup cols="2">
<colspec colnum="1" colname="c1" colwidth="1*"/>
<colspec colnum="2" colname="c2" colwidth="1*"/>
<tbody>
<row>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Drug Class</span></emphasis><newline/>
Barbiturate<newline count="2"/>
<emphasis effect="bold"><span class="blue-text">Mechanism of Action</span></emphasis><newline/>
Inhibits the central nervous system by enhancing GABA, which slows activity in the brain<newline/>
</entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Drug Dosage</span></emphasis><newline/>
Individualized based on disease process.<newline count="2"/>
<emphasis effect="bold"><span class="blue-text">Tablet</span></emphasis><newline/>
<emphasis effect="italics">Adults:</emphasis> 50–100 mg orally 2 to 3 times daily. Titrate based on response and therapeutic drug monitoring.<newline/>
<emphasis effect="italics">Children:</emphasis> Loading dose of 15–20 mg/kg produces blood levels of about 20 mcg/mL shortly after administration.<newline count="2"/>
<emphasis effect="bold"><span class="blue-text">Elixir</span></emphasis><newline/>
<emphasis effect="italics">Adults</emphasis>: 60–200 mg daily.<newline/>
<emphasis effect="italics">Children:</emphasis> 3–6 mg/kg/day.<newline count="2"/>
<emphasis effect="bold"><span class="blue-text">Intramuscular (IM) or intravenous (IV)</span></emphasis><newline/>
<emphasis effect="italics">Adults</emphasis>: 20–320 mg repeated every 6 hours as necessary.<newline/>
<emphasis effect="italics">Children:</emphasis> 4–6 mg/kg/day for 7–10 days to blood level of 10–15 mcg/mL or 10–15 mg/kg/day.<newline/>
</entry>
</row>
<row>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Indications</span></emphasis><newline/>
To treat seizures<newline/>
As a sedative<newline count="2"/>
<emphasis effect="bold"><span class="blue-text">Therapeutic Effects</span></emphasis><newline/>
Reduces seizures<newline/>
Enhances sleep<newline/>
</entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Drug Interactions</span></emphasis><newline/>
Anticoagulants<newline/>
Corticosteroids<newline/>
Griseofulvin<newline/>
Doxycycline<newline/>
Phenytoin, sodium valproate, valproic acid<newline/>
Monoamine oxidase inhibitors (MAOIs)<newline/>
Estradiol, estrone, progesterone, and other steroidal hormones<newline/>
Other central nervous system depressants<newline count="2"/>
<emphasis effect="bold"><span class="blue-text">Food Interactions</span></emphasis><newline/>
No significant interactions<newline/>
</entry>
</row>
<row>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Adverse Effects</span></emphasis><newline/>
Central nervous system depression (drowsiness, lethargy, vertigo, drowsiness)<newline/>
Respiratory depression<newline/>
Nausea<newline/>
Vomiting<newline/>
Headache<newline/>
</entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Contraindications</span></emphasis><newline/>
Hypersensitivity<newline/>
Hepatic failure<newline/>
Respiratory disease<newline count="2"/>
Caution:<newline/>
Monitor closely for drug addiction and dependence<newline count="2"/>
Caution also advised during pregnancy because drug may cause fetal malformations<newline/>
</entry>
</row>
</tbody>
</tgroup>
<caption><emphasis effect="bold">Drug Prototype: Phenobarbital</emphasis> (source: https://dailymed.nlm.nih.gov/dailymed/)</caption>
</table>
</section>
<section id="sect-00011">
<title>Succinates</title>
<para id="para-00020"><term class="no-emphasis" id="term-00028">Succinates</term> are a class of drugs that are used to treat seizures, including petit mal seizures. Succinates reduce the amount of calcium available for nerve activity by blocking calcium channels in the brain; abnormal electrical activity in the brain is then reduced, which helps to decrease the occurrence of seizures. Adverse effects include gastrointestinal upset, drowsiness, lethargy, hiccups, and headaches. They are contraindicated in persons with hypersensitivity to succinates or their properties and should be used cautiously in clients with renal or hepatic insufficiency (Hanrahan &amp; Carson, 2022).</para>
<para id="para-00021"><term class="no-emphasis" id="term-00029">Ethosuximide (Zarontin)</term> is the most used succinate. <link target-id="table-00003" document="m00263"/> is a drug prototype table for succinates featuring ethosuximide. It lists drug class, mechanism of action, adult and <term class="no-emphasis" id="term-00030">pediatric dosages</term>, indications, therapeutic effects, drug and food interactions, adverse effects, and contraindications.</para> 
<table class="vertically-tight" id="table-00003">
<tgroup cols="2">
<colspec colnum="1" colname="c1" colwidth="1*"/>
<colspec colnum="2" colname="c2" colwidth="1*"/>
<tbody>
<row>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Drug Class</span></emphasis><newline/>
Anticonvulsant<newline count="2"/>
<emphasis effect="bold"><span class="blue-text">Mechanism of Action</span></emphasis><newline/>
Blocks calcium channels in the brain, reducing the amount of calcium available for neuronal activity
</entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Drug Dosage</span></emphasis><newline/>
Individualized based on disease process.<newline count="2"/>
<emphasis effect="italics">Adults:</emphasis> Oral dose of 500 mg daily (typically in 2 divided doses).<newline/>
Upward titration by 250 mg every 4 to 7 days to keep plasma ranges of 40 to 100 mcg/mL.<newline count="2"/>
<emphasis effect="italics">Children:</emphasis> The <emphasis effect="italics">initial</emphasis> oral dose for clients 3 to 6 years of age is 1 capsule (250 mg) daily; for clients 6 years of age and older, 2 capsules (500 mg) daily.</entry>
</row>
<row>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Indications</span></emphasis><newline/>
To treat seizures<newline count="2"/>
<emphasis effect="bold"><span class="blue-text">Therapeutic Effects</span></emphasis><newline/>
Reduces seizures</entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Drug Interactions</span></emphasis><newline/>
Phenytoin<newline/>
Valproic acid<newline count="2"/>
<emphasis effect="bold"><span class="blue-text">Food Interactions</span></emphasis><newline/>
No significant interactions</entry>
</row>
<row>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Adverse Effects</span></emphasis><newline/>
Gastrointestinal upset (anorexia, nausea/vomiting, diarrhea, abdominal pain)<newline/>
Leukopenia<newline/>
Drowsiness<newline/>
Headache<newline/>
Dizziness<newline/>
Hiccups<newline/>
Pruritus/rash
</entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Contraindications</span></emphasis><newline/>
Hypersensitivity<newline count="2"/>
Caution:<newline/>
Use cautiously in people who are taking other anticonvulsant drugs as it may increase their serum levels<newline count="2"/>
Caution also advised during pregnancy as this drug may cause fetal malformations</entry>
</row>
</tbody>
</tgroup>
<caption><emphasis effect="bold">Drug Prototype: Ethosuximide</emphasis> (source: https://dailymed.nlm.nih.gov/dailymed/)</caption>
</table>
</section>
<section id="sect-00012">
<title>Benzodiazepines</title>
<para id="para-00022"><term class="no-emphasis" id="term-00031">Benzodiazepines</term> are a class of drug that act on the benzodiazepine receptors (BZ-Rs) in the central nervous system. They work by enhancing the activity of the neurotransmitter GABA, which is inhibitory and slows brain activity. Dosing is individualized and depends on the drug being used. Benzodiazepines such as clonazepam, clorazepate, and diazepam are commonly prescribed to treat seizures.</para>
<para id="para-00023">Nurses should note that these drugs can result in sedation and use of these drugs in late pregnancy can result in sedation (respiratory depression, lethargy, hypotonia) and/or withdrawal symptoms (hyperreflexia, irritability, restlessness, tremors, inconsolable crying, and feeding difficulties) in newborns.</para>
<para id="para-00024"><link target-id="table-00004" document="m00263"/> lists common benzodiazepines and typical routes and dosing for adult and <term class="no-emphasis" id="term-00032">pediatric clients</term>.</para>
<table class="vertically-tight full-width" id="table-00004">
<tgroup cols="2">
<colspec colnum="1" colname="c1" colwidth="1*"/>
<colspec colnum="2" colname="c2" colwidth="2*"/>
<tbody>
<row>
<entry valign="top" align="center"><emphasis effect="bold"><span class="blue-text">Drug</span></emphasis></entry>
<entry valign="top" align="center"><emphasis effect="bold"><span class="blue-text">Routes and Dosage Ranges</span></emphasis></entry>
</row>
<row>
<entry valign="middle" align="center"><term class="no-emphasis" id="term-00033">Clonazepam</term><newline/>
(<term class="no-emphasis" id="term-00034">Klonopin</term>)</entry>
<entry valign="top" align="left"><emphasis effect="italics">Adults:</emphasis> Initial oral dose of 1.5 mg/day divided into 3 doses.<newline/>
  Increase dose by 0.5–1 mg every 3 days until seizures are adequately controlled.<newline count="2"/>
<emphasis effect="italics">Children</emphasis>: Initial dose for infants and children (up to 10 years of age or 30 kg of body weight) should be 0.01–0.03 mg/kg/day but not exceed 0.05 mg/kg/day given in 2 or 3 divided doses.<newline count="2"/>
Dosage should be increased by no more than 0.25–0.5 mg every third day until a daily maintenance dose of 0.1–0.2 mg/kg of body weight has been reached and seizures are controlled.<newline count="2"/>
Whenever possible, the daily dose should be divided into 3 equal doses. If this is not feasible, give the largest dose before bedtime.</entry>
</row>
<row>
<entry valign="middle" align="center"><term class="no-emphasis" id="term-00035">Clorazepate</term></entry>
<entry valign="top" align="left"><emphasis effect="italics">Adults</emphasis>: The maximum recommended initial dose in clients over 12 years old is 7.5 mg 3 times daily. Increase dose by no more than 7.5 mg every week to a maximum of 90 mg/day.<newline count="2"/>
<emphasis effect="italics">Children (9</emphasis><emphasis effect="italics">–12 years):</emphasis> The maximum recommended initial dose is 7.5 mg 2 times a daily.<newline count="2"/>
Increase dose by no more than 7.5 mg every week not to exceed 60 mg/day.</entry>
</row>
<row>
<entry valign="middle" align="center"><term class="no-emphasis" id="term-00036">Diazepam</term><newline/>
(<term class="no-emphasis" id="term-00037">Valium</term>, <term class="no-emphasis" id="term-00067">Diastat</term>, <term class="no-emphasis" id="term-00068">Valtoco</term>)</entry>
<entry valign="top" align="left"><emphasis effect="italics">Adults:</emphasis> 5–10 mg intravenously slowly; if seizure continues or recurs, may repeat if necessary at 10- to 15-minute intervals up to a maximum dose of 30 mg.<newline count="2"/>
<emphasis effect="italics">Children (Children 3 months up to 17 years of age with status epilepticus):</emphasis><newline/>
<emphasis effect="italics">First dose:</emphasis> 0.2 mg/kg (maximum 8 mg) by slow intravenous push (1 minute in duration).<newline/>
<emphasis effect="italics">Second dose:</emphasis> (If necessary; 5 minutes after the first dose): 0.1 mg/kg (maximum 4 mg) by slow intravenous push (1 minute in duration).<newline count="2"/>
<emphasis effect="italics">Adults:</emphasis> 2–10 mg orally 2–4 times daily.<newline count="2"/>
<emphasis effect="italics">Children:</emphasis> Because of varied responses to central nervous system–acting drugs, initiate therapy with lowest dose and increase as required.<newline count="2"/>
Not for use in children under 6 months.<newline/>
1–2.5 mg, 3 or 4 times daily orally initially; increase gradually as needed and tolerated.</entry>
</row>
<row>
  <entry valign="middle" align="center"><term class="no-emphasis" id="term-00072">Lorazepam</term><newline/>
    (<term class="no-emphasis" id="term-00073">Ativan</term>)</entry>
    <entry valign="top" align="left">Individualized based on disease process.<newline/>
      <emphasis effect="italics">Adults:</emphasis> Oral dosing of 2–6 mg/day given in divided doses 2 to 3 times daily.<newline count="2"/>
      <emphasis effect="italics">Adults:</emphasis> Intravenous dosing of 4 mg given slowly.<newline/>
      If seizure continues or recurs after 10- to 15-minute observation period, an additional 4 mg IV may be slowly administered.<newline count="2"/>
      <emphasis effect="italics">Children:</emphasis> Not recommended in children less than 18 years of age.</entry>
    </row>
</tbody>
</tgroup>
<caption><emphasis effect="bold">Drug Emphasis Table: Benzodiazepines</emphasis> (source: https://dailymed.nlm.nih.gov/dailymed/)</caption>
</table>
</section>
<section id="sect-00013">
<title>Adverse Effects and Contraindications</title>
<para id="para-00025">Common adverse effects of benzodiazepines include respiratory depression, drowsiness, confusion, headache, dizziness, tremor, and gastrointestinal upset. Benzodiazepines are contraindicated in hypersensitivity to the drug and its properties, in angle closure glaucoma, and with concomitant use with opioids. An increased risk of congenital malformations and other developmental abnormalities associated with benzodiazepine use during pregnancy has been identified.</para>
<para id="para-00026">Seizure rescue with benzodiazepines is a commonly used approach to manage seizures quickly and effectively. Benzodiazepines suppress excessive electrical activity in the brain. When a seizure occurs, administering a benzodiazepine promptly can help terminate the seizure and prevent its progression These medications can be administered orally, intravenously, intramuscularly, and via other routes depending on the situation and available resources.</para>
<para id="para-00027">The goal of seizure rescue with benzodiazepines is to provide rapid and effective control of seizures while ensuring the safety and well-being of the client. Benzodiazepines are a short-term solution for seizure management. Long-term treatment plans and adjustments should be made in collaboration with a health care provider to address the underlying cause of the seizure and prevent future occurrences.</para>
<para id="para-00028">Another widely used benzodiazepine for treating seizures is lorazepam. <link target-id="table-00005" document="m00263"/> is a drug prototype table for benzodiazepines featuring lorazepam. It lists drug class, mechanism of action, adult dosage, indications, therapeutic effects, drug and food interactions, adverse effects, and contraindications.</para>
<table class="vertically-tight" id="table-00005">
<tgroup cols="2">
<colspec colnum="1" colname="c1" colwidth="1*"/>
<colspec colnum="2" colname="c2" colwidth="1*"/>
<tbody>
<row>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Drug Class</span></emphasis><newline/>
Benzodiazepine<newline count="2"/>
<emphasis effect="bold"><span class="blue-text">Mechanism of Action</span></emphasis><newline/>
Binds to the benzodiazepine receptors on the postsynaptic GABA-A ligand-gated chloride channel neuron in the central nervous system, thereby enhancing the inhibitory effects of GABA</entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Drug Dosage</span></emphasis><newline/>
Individualized based on disease process.<newline/>
<emphasis effect="italics">Adults:</emphasis> Oral dosing of 2–6 mg/day given in divided doses 2 to 3 times daily.<newline count="2"/>
<emphasis effect="italics">Adults:</emphasis> Intravenous dosing of 4 mg given slowly.<newline/>
If seizure continues or recurs after 10- to 15-minute observation period, an additional 4 mg IV may be slowly administered.<newline count="2"/>
<emphasis effect="italics">Children:</emphasis> Not recommended in children less than 18 years of age.</entry>
</row>
<row>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Indications</span></emphasis><newline/>
To treat seizures<newline/>
Preanesthetic<newline count="2"/>
<emphasis effect="bold"><span class="blue-text">Therapeutic Effects</span></emphasis><newline/>
Reduces seizures<newline/>
Sedation</entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Drug Interactions</span></emphasis><newline/>
Opioids<newline/>
Scopolamine<newline/>
Probenecid<newline count="2"/>
<emphasis effect="bold"><span class="blue-text">Food Interactions</span></emphasis><newline/>
No significant interactions</entry>
</row>
<row>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Adverse Effects</span></emphasis><newline/>
Hypotension<newline/>
Confusion<newline/>
Somnolence<newline/>
Headache<newline/>
Leukocytosis<newline/>
Respiratory suppression</entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Contraindications</span></emphasis><newline/>
Hypersensitivity<newline/>
Acute narrow angle glaucoma<newline/>
Respiratory insufficiency<newline/>
Pregnancy/breastfeeding<newline count="2"/>
Caution:<newline/>
Use cautiously with other drugs that suppress the central nervous system due to respiratory suppression</entry>
</row>
</tbody>
</tgroup>
<caption><emphasis effect="bold">Drug Prototype: <term class="no-emphasis" id="term-00038">Lorazepam</term></emphasis> (source: https://dailymed.nlm.nih.gov/dailymed/)</caption>
</table>
<note class="black-box" id="note-00002">
<para id="para-00029"><emphasis effect="bold">Benzodiazepines</emphasis></para>
<para id="para-00030">Benzodiazepines—when used in combination with opioid drugs—may depress the central nervous system, causing serious adverse effects including respiratory depression and death.</para>
</note>
<note class="clinical-tip" id="note-00003">
<title>Lorazepam Intravenous Administration</title>
<para id="para-00031">Intravenous administration of lorazepam should be via slow intravenous push (2 mg/minute) for active seizures. If respiratory depression develops, flumazenil should be used as a competitive antagonist to reverse the effects of the lorazepam (Ghiasi et al., 2023).</para>
</note>
<note class="special-considerations" id="note-00004">
<title><term class="no-emphasis" id="term-00039">Substance Abuse</term></title>
<para id="para-00032"><term class="no-emphasis" id="term-00040">Barbiturates</term> and <term class="no-emphasis" id="term-00041">benzodiazepines</term> are highly addictive and can result in dependence, tolerance, and even overdose. It is important for the health care provider to consider the client’s situation and perform a thorough medical and social history, including a review of the client’s history for addiction or substance abuse.</para>
<list list-type="bulleted" id="list-00009">
<item><term class="no-emphasis" id="term-00042">Drug tolerance</term> occurs when someone abuses a substance over a long period of time.</item>
<item><term class="no-emphasis" id="term-00043">Dependence</term> occurs when someone abuses high doses of a substance and they cannot function normally without the use of the substance.</item>
<item><term class="no-emphasis" id="term-00044">Substance use disorder</term> occurs when someone is unable to control the use of the substance and they cannot stop using the substance.</item>
<item><term class="no-emphasis" id="term-00045">Overdose</term> occurs when someone takes in a toxic amount of a substance. Overdose can lead to coma or even death.</item>
</list>
<para id="para-00033">(Jahan &amp; Burgess, 2022)</para>
<para id="para-00034">The <link url="https://openstax.org/r/nidanih">National Institute on Drug Abuse (NIDA)</link> is the leading federal agency supporting scientific research on drug use and addiction. The NIDA provides research, education, and training resources to help end addiction and play a role in the <link url="https://openstax.org/r/healnih">National Institute of Health HEAL (helping to end long term addiction) Program</link>, which looks at addiction and substance use disorders as a public health emergency in the United States.</para>
<para id="para-00035">The <link url="https://openstax.org/r/samhsa">Substance Abuse and Mental Health Services Administration (SAMHSA)</link> is a national helpline and confidential treatment referral service that provides clients and their families with needed resources regarding substance abuse disorders and mental health issues.</para>
</note>
</section>
<section id="sect-00014">
<title>Iminostilbenes</title>
<para id="para-00036"><term class="no-emphasis" id="term-00046">Iminostilbenes</term> are a class of anticonvulsant drug in which the compounds are structurally related to cyclic antidepressants. This class of drug shows efficacy in the first-line treatment for seizures. Iminostilbenes inhibit neuronal excitability by enhancing GABA; this drug requires therapeutic monitoring. Adverse reactions include urticaria, photosensitivity, congestive heart failure, edema, dyspnea, acute urinary retention, drowsiness, dizziness, coordination disturbances, headache, fatigue, abdominal pain, agranulocytosis, hyponatremia/SIADH, and leukopenia. Iminostilbenes are contraindicated in individuals with previous bone marrow depression and with hypersensitivity to the drug or its constituents; they should not be administered with tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, nefazodone, and delavirdine (Magheru et al., 2022).</para>
<note class="black-box" id="note-00005">
<para id="para-00037"><emphasis effect="bold">Carbamazepine</emphasis></para>
<para id="para-00038">Carbamazepine may cause serious adverse effects including aplastic anemia and agranulocytosis.</para>
<para id="para-00039">Carbamazepine may cause serious dermatologic reactions including toxic epidermal necrolysis and Stevens-Johnson syndrome.</para>
</note>
<para id="para-00040">The most common iminostilbene used in the treatment of seizures is <term class="no-emphasis" id="term-00047">carbamazepine</term> (<term class="no-emphasis" id="term-00048">Tegretol</term>). <link target-id="table-00006" document="m00263"/> is a drug prototype table for iminostilbenes featuring carbamazepine. It lists drug class, mechanism of action, adult and pediatric dosages, indications, therapeutic effects, drug and food interactions, adverse effects, and contraindications.</para>
<table class="vertically-tight" id="table-00006">
<tgroup cols="2">
<colspec colnum="1" colname="c1" colwidth="1*"/>
<colspec colnum="2" colname="c2" colwidth="1*"/>
<tbody>
<row>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Drug Class</span></emphasis><newline/>
Anticonvulsant<newline count="2"/>
<emphasis effect="bold"><span class="blue-text">Mechanism of Action</span></emphasis><newline/>
Inhibits neuronal excitability by enhancing GABA, which decreases brain activity</entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Drug Dosage</span></emphasis><newline/>
Individualized based on disease process and serum blood levels.<newline count="2"/>
<emphasis effect="italics">Adults and children over 12 years of age:</emphasis> Initial dose of 200 mg orally twice daily.<newline count="2"/>
Increase at weekly intervals by adding up to 200 mg/day until the optimal response is obtained.<newline count="2"/>
Maintenance dosage to the minimum effective level, usually 800–1200 mg daily.<newline count="2"/>
Extended release: Initial dose of 200 mg orally twice daily.<newline count="2"/>
Increase weekly by adding 200 mg/day using a twice daily regimen until optimal response is reached.<newline/>
Maximum dose: 800–1200 mg daily.<newline count="2"/>
<emphasis effect="italics">Children 6–12 years of age:</emphasis><newline/>
Initial dose of 100 mg twice daily for tablets (200 mg/day).<newline count="2"/>
Increase at weekly intervals by adding up to 100 mg/day using a 3–4 times daily regimen of carbamazepine tablets until the optimal response is obtained.<newline count="2"/>
Dosage generally should not exceed 1000 mg daily.<newline count="2"/>
<emphasis effect="italics">Maintenance</emphasis><emphasis effect="italics">:</emphasis> Adjust dosage to the minimum effective level, usually 400–800 mg daily.<newline count="2"/>
<emphasis effect="italics">Children under 6 years of age:</emphasis><newline/>
Initial dose of 10–20 mg/kg twice daily or 3 times daily as tablets.<newline count="2"/>
Increase weekly to achieve optimal clinical response administered 3 times daily or 4 times daily.<newline count="2"/>
<emphasis effect="italics">Maintenance</emphasis><emphasis effect="italics">:</emphasis> Typically, optimal clinical response is achieved at daily doses below 35 mg/kg.<newline count="2"/>
If satisfactory clinical response not achieved, measure plasma levels to determine if they are in the therapeutic range.<newline count="2"/>
No recommendation regarding safety of carbamazepine for use at doses above 35 mg/kg/24 hours.</entry>
</row>
<row>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Indications</span></emphasis><newline/>
To treat seizures<newline count="2"/>
<emphasis effect="bold"><span class="blue-text">Therapeutic Effects</span></emphasis><newline/>
Reduces seizure activity<newline/>
Sedation</entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Drug Interactions</span></emphasis><newline/>
No significant drug interactions, other than contraindications listed below<newline count="2"/>
<emphasis effect="bold"><span class="blue-text">Food Interactions</span></emphasis><newline/>
No significant interactions</entry>
</row>
<row>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Adverse Effects</span></emphasis><newline/>
Photosensitivity<newline/>
Edema<newline/>
Dyspnea<newline/>
Urinary retention<newline/>
Drowsiness<newline/>
Coordination disturbances<newline/>
Headache<newline/>
Fatigue<newline/>
Agranulocytosis<newline/>
Leukopenia<newline/>
Bone marrow depression</entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Contraindications</span></emphasis><newline/>
Hypersensitivity<newline/>
Bone marrow suppression<newline/>
Tricyclic antidepressants<newline/>
MAO inhibitors<newline/>
Nefazodone<newline/>
Delavirdine<newline count="2"/>
Caution:<newline/>
Monitor closely for serious dermatologic reactions including toxic epidermal necrolysis and Stevens-Johnson syndrome<newline/>
Monitor closely for hyponatremia and SIADH</entry>
</row>
</tbody>
</tgroup>
<caption><emphasis effect="bold">Drug Prototype: Carbamazepine</emphasis> (source: https://dailymed.nlm.nih.gov/dailymed/)</caption>
</table>
</section>
<section id="sect-00015">
<title>Valproates</title>
<para id="para-00041"><term class="no-emphasis" id="term-00049">Valproates</term> are anticonvulsants and mood stabilizers used in the treatment of seizures and bipolar disorder. Valproates act on GABA levels in the central nervous system, blocking voltage-gated sodium, potassium, and calcium ion channels causing decreasing brain activity. Adverse reactions include headache, somnolence, dizziness, drowsiness, thrombocytopenia, tremor, alopecia, emotional lability, petechiae, rash, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) elevation, tinnitus, and photosensitivity. Valproates are contraindicated in individuals with hepatic disorders and in those who have hypersensitivity to components of the drug.</para>
<note class="black-box" id="note-00006">
<para id="para-00042"><emphasis effect="bold">Valproates</emphasis></para>
<para id="para-00043">Valproates may cause serious adverse effects including pancreatitis, abnormal bleeding, and clotting times. Valproates are known to cause abnormalities in the development of the fetus.</para>
</note>
<para id="para-00044">Therapeutic drug monitoring measures the concentration of a valproic acid in the client’s blood and ensures that the drug is within the therapeutic range by adjusting the dosage, if necessary. Therapeutic range for valproic acid varies depending on the indication being treated. Generally, the total serum concentration of valproic acid is maintained between 50 and 100 µg/mL for epilepsy. However, individualized target ranges may be established based on factors such as age, comorbidities, concomitant medications, and treatment responses.</para>
<para id="para-00045">The most common valproate is <term class="no-emphasis" id="term-00050">valproic acid</term> (Rahman &amp; Nguyen, 2022). <link target-id="table-00007" document="m00263"/> is a drug prototype table for valproates featuring valproic acid. It lists drug class, mechanism of action, adult and <term class="no-emphasis" id="term-00051">pediatric dosages</term>, indications, therapeutic effects, drug and food interactions, adverse effects, and contraindications.</para>
<table class="vertically-tight" id="table-00007">
<tgroup cols="2">
<colspec colnum="1" colname="c1" colwidth="1*"/>
<colspec colnum="2" colname="c2" colwidth="1*"/>
<tbody>
<row>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Drug Class</span></emphasis><newline/>
Anticonvulsant and mood stabilizer<newline count="2"/>
<emphasis effect="bold"><span class="blue-text">Mechanism of Action</span></emphasis><newline/>
Acts on the GABA levels in the central nervous system: blocking voltage-gated sodium, potassium, and calcium ion channels and decreasing brain activity</entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Drug Dosage</span></emphasis><newline/>
Individualized based on disease process.<newline count="2"/>
<emphasis effect="italics">Adults and children aged 10 years or older:</emphasis> 15 mg/kg/day.<newline count="2"/>
Increase at 1-week intervals by 5–10 mg/kg/day until seizures are controlled or side effects preclude further increases.<newline count="2"/>
<emphasis effect="italics">Maximum recommended dosage:</emphasis> 60 mg/kg/day.<newline count="2"/>
If total daily dose exceeds 250 mg, it should be given in divided doses.<newline count="2"/>
Therapeutic drug monitoring range between 50–100 µg/mL.</entry>
</row>
<row>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Indications</span></emphasis><newline/>
To treat seizures<newline/>
To treat bipolar disorder<newline count="2"/>
<emphasis effect="bold"><span class="blue-text">Therapeutic Effects</span></emphasis><newline/>
Reduces seizure activity<newline/>
Reduces bipolar symptoms of mania</entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Drug Interactions</span></emphasis><newline/>
Amitriptyline/nortriptyline<newline/>
Carbamazepine<newline/>
Clonazepam<newline/>
Diazepam<newline/>
Ethosuximide<newline/>
Lamotrigine<newline/>
Phenobarbital<newline/>
Phenytoin<newline/>
Propofol<newline/>
Rufinamide<newline/>
Tolbutamide<newline/>
Warfarin<newline/>
Zidovudine<newline count="2"/>
<emphasis effect="bold"><span class="blue-text">Food Interactions</span></emphasis><newline/>
No significant interactions</entry>
</row>
<row>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Adverse Effects</span></emphasis><newline/>
Headache<newline/>
Somnolence<newline/>
Dizziness<newline/>
Drowsiness<newline/>
Thrombocytopenia<newline/>
Emotional lability<newline/>
Rash<newline/>
Elevated liver enzymes<newline/>
Tinnitus</entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Contraindications</span></emphasis><newline/>
Hypersensitivity<newline/>
Hepatic insufficiency<newline/>
Bone marrow depression<newline/>
Pregnancy<newline count="2"/>
Caution:<newline/>
Monitor closely for suicidal behavior and ideation<newline count="2"/>
Should be stopped if client develops acute pancreatitis</entry>
</row>
</tbody>
</tgroup>
<caption><emphasis effect="bold">Drug Prototype: Valproic Acid</emphasis> (source: https://dailymed.nlm.nih.gov/dailymed/)</caption>
</table>
</section>
<section id="sect-00016">
<title>Pyrrolidine Derivatives</title>
<para id="para-00046"><term class="no-emphasis" id="term-00052">Pyrrolidine derivatives</term> are novel anticonvulsant drugs used to treat seizures that were FDA approved in 2000. Pyrrolidine derivatives come in IV and oral formularies. Adverse effects include abdominal pain, nausea, anorexia, leukopenia, headache, mood swings, fatigue, somnolence, confusion, and increased risk for suicide. They are contraindicated with hypersensitivity to any of the drug’s components and in individuals with renal impairment.</para>
<note class="black-box" id="note-00007">
<para id="para-00047"><emphasis effect="bold">Levetiracetam</emphasis></para>
<para id="para-00048">Levetiracetam may cause serious or life-threatening behavioral manifestations and psychotic symptoms, including aggression, hostility, and homicidal ideation.</para>
</note>
<para id="para-00049"><term class="no-emphasis" id="term-00053">Levetiracetam</term> (<term class="no-emphasis" id="term-00069">Keppra</term>) is the most used pyrrolidine derivative. <link target-id="table-00008" document="m00263"/> is a drug prototype table for pyrrolidine derivatives featuring levetiracetam. It lists drug class, mechanism of action, adult and <term class="no-emphasis" id="term-00054">pediatric dosages</term>, indications, therapeutic effects, drug and food interactions, adverse effects, and contraindications.</para>
<table class="vertically-tight" id="table-00008">
<tgroup cols="2">
<colspec colnum="1" colname="c1" colwidth="1*"/>
<colspec colnum="2" colname="c2" colwidth="1*"/>
<tbody>
<row>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Drug Class</span></emphasis><newline/>
Pyrrolidines<newline count="2"/>
<emphasis effect="bold"><span class="blue-text">Mechanism of Action</span></emphasis><newline/>
Binds to a unique synaptic vesicle protein 2A (SV2A)—SV2A protein is a part of secretory vesicle membranes that mediates calcium-dependent vesicular neurotransmitter release; the binding of levetiracetam to SV2A appears to decrease the rate of vesicle release</entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Drug Dosage</span></emphasis><newline/>
Individualized based on disease process.<newline count="2"/>
<emphasis effect="italics">Adults and adolescents 16 years of age or older:</emphasis> Initiate treatment with a daily dose of 1000 mg/day, given as twice-daily dosing (500 mg twice daily).<newline count="2"/>
Additional dosing increments may be given (1000 mg/day additional every 2 weeks) to a maximum recommended daily dose of 3000 mg.<newline count="2"/>
<emphasis effect="italics">Children younger than 16 years of age:</emphasis><newline/> <emphasis effect="italics">1 month to &lt;6 months:</emphasis> Initiate treatment with a daily dose of 14 mg/kg in 2 divided doses (7 mg/kg twice daily) Increase the daily dose every 2 weeks by increments of 14 mg/kg to the recommended daily dose of 42 mg/kg (21 mg/kg twice daily). In the clinical trial, the mean daily dose was 35 mg/kg in this age group.<newline count="2"/>
<emphasis effect="italics">6 months to &lt;4 years:</emphasis> Initiate treatment with a daily dose of 20 mg/kg in 2 divided doses (10 mg/kg twice daily). Increase the daily dose in 2 weeks by an increment of 20 mg/kg to the recommended daily dose of 50 mg/kg (25 mg/kg twice daily). If a client cannot tolerate a daily dose of 50 mg/kg, the daily dose may be reduced. In the clinical trial, the mean daily dose was 47 mg/kg in this age group.<newline count="2"/>
<emphasis effect="italics">4 years to &lt;16 years:</emphasis> Initiate treatment with a daily dose of 20 mg/kg in 2 divided doses (10 mg/kg twice daily). Increase the daily dose every 2 weeks by increments of 20 mg/kg to the recommended daily dose of 60 mg/kg (30 mg/kg twice daily). If a client cannot tolerate a daily dose of 60 mg/kg, the daily dose may be reduced. In the clinical trial, the mean daily dose was 44 mg/kg.<newline count="2"/>
The maximum daily dose is 3000 mg/day.</entry>
</row>
<row>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Indications</span></emphasis><newline/>
To treat seizures<newline count="2"/>
<emphasis effect="bold"><span class="blue-text">Therapeutic Effects</span></emphasis><newline/>
Reduces seizures<newline/>
Sedation</entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Drug Interactions</span></emphasis><newline/>
Baclofen<newline/>
Melatonin<newline/>
Opioids<newline/>
Trazodone<newline count="2"/>
<emphasis effect="bold"><span class="blue-text">Food Interactions</span></emphasis><newline/>
No significant interactions</entry>
</row>
<row>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Adverse Effects</span></emphasis><newline/>
Somnolence<newline/>
Fatigue<newline/>
Rash<newline/>
Coordination difficulties<newline/>
Emotional lability<newline/>
Headache</entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Contraindications</span></emphasis><newline/>
Hypersensitivity<newline count="2"/>
Caution:<newline/>
Monitor closely for behavioral abnormalities such as increase in aggression, agitation, or anger and for psychotic symptoms such as hallucinations and delirium</entry>
</row>
</tbody>
</tgroup>
<caption><emphasis effect="bold">Drug Prototype: Levetiracetam</emphasis> (source: https://dailymed.nlm.nih.gov/dailymed/)</caption>
</table>
</section>
<section id="sect-00017">
<title>Other Anticonvulsants</title>
<para id="para-00050">There are many other anticonvulsants on the market; novel drugs continue to appear as treatment options improve. <link target-id="table-00009" document="m00263"/> lists common anticonvulsant drugs and typical routes and dosing for adult and <term class="no-emphasis" id="term-00055">pediatric clients</term>.</para>
<note class="black-box" id="note-00008">
<para id="para-00051"><emphasis effect="bold">Lamotrigine</emphasis></para>
<para id="para-00052">Lamotrigine may cause serious dermatologic reactions such as Stevens-Johnson syndrome or toxic epidermal necrosis.</para>
</note>
<table class="vertically-tight full-width" id="table-00009">
<tgroup cols="5">
<colspec colnum="1" colname="c1" colwidth="1*"/>
<colspec colnum="2" colname="c2" colwidth="2*"/>
<colspec colnum="3" colname="c3" colwidth="2*"/>
<colspec colnum="4" colname="c4" colwidth="2*"/>
<colspec colnum="5" colname="c5" colwidth="2*"/>
<thead>
<row>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Drug</span></emphasis></entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Class and Indication</span></emphasis></entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Mechanism of Action</span></emphasis></entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Adverse Effects and Contraindications</span></emphasis></entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Dosage and Routes of Administration</span></emphasis></entry>
</row>
</thead>
<tbody>
<row>
<entry valign="middle" align="center"><term class="no-emphasis" id="term-00056">Gabapentin</term><newline/>
  (<term class="no-emphasis" id="term-00057">Neurontin</term>)</entry>
<entry valign="top" align="left">Anticonvulsant<newline count="2"/>
<emphasis effect="italics">Indication:</emphasis> Adjunctive therapy for partial onset seizures, with or without secondary generalization, in adults and children 3 years and older with epilepsy</entry>
<entry valign="top" align="left">Increases the concentration and probably the rate of synthesis of GABA in brain, which may enhance non-vesicular GABA release during seizures</entry>
<entry valign="top" align="left"><emphasis effect="italics">Adverse Effects:</emphasis> <newline/>
in clients >12 years of age: Somnolence, dizziness, ataxia, fatigue, and nystagmus<newline count="2"/>
<emphasis effect="italics">In clients 3–12 years:</emphasis> Viral infection, fever, nausea and/or vomiting, somnolence, and hostility<newline count="2"/>
<emphasis effect="italics">Contraindications:</emphasis> Hypersensitivity to the drug or its ingredients</entry>
<entry valign="top" align="left"><emphasis effect="italics">In clients 12 years of age and above:</emphasis><newline/>
 Starting dose 300 mg orally 3 times daily<newline/>
Recommended maintenance is 300–600 mg 3 times daily.<newline/>
<emphasis effect="italics">In clients 3–11 years:</emphasis><newline/>
Starting dose range is 10 mg/kg/day–15 mg/kg/day orally given in 3 divided doses and the recommended maintenance dose reached by upward titration over a period of 3 days <emphasis effect="italics">Recommended maintenance dose for 3–4 years of age:</emphasis><newline/>
40 mg/kg/day orally in 3 divided doses<newline/>
<emphasis effect="italics">Recommended maintenance dose for 5–11 years of age:</emphasis><newline/>
25 mg/kg/day–35 mg/kg/day orally in 3 divided doses</entry>
</row>
<row>
<entry valign="middle" align="center"><term class="no-emphasis" id="term-00058">Lamotrigine</term><newline/>
(<term class="no-emphasis" id="term-00059">Lamictal</term>)</entry>
<entry valign="top" align="left">Anticonvulsant<newline count="2"/>
<emphasis effect="italics">Indication:</emphasis> Adjunctive therapy for partial seizures</entry>
<entry valign="top" align="left">Blocks voltage-gated sodium ion channels and inhibits presynaptic glutamate and aspartate release</entry>
<entry valign="top" align="left"><emphasis effect="italics">Adverse Effects:</emphasis> GI upset, dizziness, drowsiness, blurred vision, fatigue, and rash related to Stevens-Johnson syndrome<newline count="2"/>
<emphasis effect="italics">Contraindications:</emphasis> Hypersensitivity to the drug or its ingredients</entry>
<entry valign="top" align="left"><emphasis effect="italics">Oral dosing (in clients taking Valproate concurrently):</emphasis> <newline/>
<emphasis effect="italics">Weeks 1 and 2:</emphasis> 25 mg every other day<newline/>
<emphasis effect="italics">Weeks 3 and 4:</emphasis> 25 mg daily<newline/>
<emphasis effect="italics">Week 5 onward</emphasis>: Increase by 25–50 mg/day every 1–2 weeks<newline/>
<emphasis effect="italics">Maintenance dose:</emphasis> 200–250 mg daily<newline count="2"/><emphasis effect="italics">Extended-release oral dosing (in clients taking Valproate concurrently):</emphasis><newline/>
<emphasis effect="italics">Weeks 1 and 2:</emphasis> 25 mg every other day<newline/>
<emphasis effect="italics">Weeks 3 and 4:</emphasis> 25 mg daily<newline/>
<emphasis effect="italics">Week 5:</emphasis> 50 mg daily<newline/>
<emphasis effect="italics">Week 6:</emphasis> 100 mg daily<newline/>
<emphasis effect="italics">Week 7:</emphasis> 150 mg daily<newline/>
<emphasis effect="italics">Maintenance dose:</emphasis> 200–250 mg daily<newline/>
Maximum dose: 400 mg/day</entry>
</row>
<row>
<entry valign="middle" align="center"><term class="no-emphasis" id="term-00060">Topiramate</term><newline/>
(<term class="no-emphasis" id="term-00061">Topamax, Qudexy, Trokendi</term>)</entry>
<entry valign="top" align="left">Anticonvulsant, Other<newline count="2"/>
<emphasis effect="italics">Indication:</emphasis> Treatment of partial or generalized seizures</entry>
<entry valign="top" align="left">Stimulates GABA-A receptor activity at brain non-benzodiazepine receptor sites and reduces glutamate activity</entry>
<entry valign="top" align="left"><emphasis effect="italics">Adverse Effects:</emphasis> Drowsiness, somnolence, fatigue, coordination difficulties<newline count="2"/>
<emphasis effect="italics">Contraindications:</emphasis> <newline/>
Hypersensitivity to the drug or its ingredients</entry>
<entry valign="top" align="left"><emphasis effect="italics">Adults and children 10 years of age and older:</emphasis> Oral dosing 400 mg/day in 2 divided doses<newline count="2"/>
The dose should be achieved by titrating as follows:<newline/>
<emphasis effect="italics">Week 1:</emphasis> 25 mg in morning and evening<newline/>
<emphasis effect="italics">Week 2:</emphasis> 50 mg in morning and evening<newline/>
<emphasis effect="italics">Week 3:</emphasis> 75 mg in morning and evening<newline/>
<emphasis effect="italics">Week 4:</emphasis> 100 mg in morning and evening<newline/>
<emphasis effect="italics">Week 5:</emphasis> 150 mg in morning and evening<newline/>
<emphasis effect="italics">Week 6:</emphasis> 200 mg in morning and evening<newline/>
<emphasis effect="italics">Maximum dose:</emphasis> 400 mg/day<newline count="2"/>
<emphasis effect="italics">Children 2</emphasis>–<emphasis effect="italics">9 years of age:</emphasis> Dosing in clients 2–9 years of age based on weight<newline count="2"/>
The initial dose of topiramate tablet is 25 mg/day nightly for the first week<newline count="2"/>
The dosage can be increased to 50 mg/day (25 mg twice daily) in the second week<newline count="2"/>
During subsequent weeks, the dosage can be increased by 25–50 mg/day as tolerated<newline count="2"/>
Titration to the minimum maintenance dose should be attempted over 5–7 weeks of the total titration period<newline count="2"/>
Additional titration to a higher dose (up to the maximum maintenance dose) can be attempted at 25–50 mg/day weekly increments</entry>
</row>
<row>
<entry valign="middle" align="center"><term class="no-emphasis" id="term-00062">Lacosamide</term><newline/>
(<term class="no-emphasis" id="term-00063">Vimpat</term>, <term class="no-emphasis" id="term-00070">Motpoly XR</term>)</entry>
<entry valign="top" align="left">Anticonvulsant, Other<newline count="2"/>
<emphasis effect="italics">Indication:</emphasis> Treatment of partial seizures</entry>
<entry valign="top" align="left">Blocks voltage-gated sodium ion channels and decreases brain activity</entry>
<entry valign="top" align="left"><emphasis effect="italics">Adverse Effects:</emphasis> Dizziness, nausea, headache, fatigue, drowsiness<newline count="2"/>
<emphasis effect="italics">Contraindications:</emphasis> Hypersensitivity, second- and third-degree atrioventricular (AV) block, which may cause severe bradycardia</entry>
<entry valign="top" align="left"><emphasis effect="italics">Adults and adolescents 17 years of age or older:</emphasis> Initial oral dose of 100 mg twice daily or 200 mg single loading dose, followed 12 hours later by 100 mg twice daily<newline count="2"/>
Increase by 50 mg twice daily every week to reach maintenance dose of 150–200 mg twice daily<newline count="2"/>
<emphasis effect="italics">Children weighing over 50 kg:</emphasis> Oral initial dose 50 mg twice daily or 100 mg daily<newline count="2"/>
Increase by 50 mg twice daily or 100 mg daily every week<newline count="2"/>
<emphasis effect="italics">Maintenance dose:</emphasis> 150–200 mg twice daily or 300–400 mg daily<newline count="2"/>
<emphasis effect="italics">Children weighing 30 kg to less than 50 kg:</emphasis> Oral initial dose 1 mg/kg twice daily or 2 mg/kg daily<newline count="2"/>
Increase by 1 mg/kg twice daily or 2 mg/kg daily every week<newline count="2"/>
<emphasis effect="italics">Maintenance:</emphasis> 2 mg/kg twice daily or 4 mg/kg/day to 8 mg/kg/day<newline count="2"/>
<emphasis effect="italics">Children weighing 11 kg to less than 50 kg:</emphasis> Oral initial dose 1 mg/kg twice daily or 2 mg/kg daily<newline count="2"/>
Increase by 1 mg/kg twice daily or 2 mg/kg daily every week<newline count="2"/>
<emphasis effect="italics">Maintenance:</emphasis> 3 mg/kg to 6 mg/kg twice daily or 6 mg/kg/day to 12 mg/kg/day</entry>
</row>
<row>
<entry valign="middle" align="center"><term class="no-emphasis" id="term-00064">Zonisamide</term><newline/>
(<term class="no-emphasis" id="term-00065">Zonegran</term>, <term class="no-emphasis" id="term-00071">Zonisade</term>)</entry>
<entry valign="top" align="left">Sulfonamide anticonvulsant<newline count="2"/>
<emphasis effect="italics">Indication:</emphasis> Adjunctive therapy for partial seizures</entry>
<entry valign="top" align="left">Blocks voltage-gated sodium ion channels and inhibits presynaptic glutamate and aspartate release</entry>
<entry valign="top" align="left"><emphasis effect="italics">Adverse Effects:</emphasis> Headache, fatigue, coordination difficulties, visual disturbances, drowsiness<newline count="2"/>
<emphasis effect="italics">Contraindications:</emphasis><newline/>
Hypersensitivity to the drug or its ingredients</entry>
<entry valign="top" align="left"><emphasis effect="italics">Adults and adolescents 16 years of age and older:</emphasis> Oral dosing initial dose 100 mg daily<newline count="2"/>
After 2 weeks the dose may be increased to 200 mg/day for at least 2 weeks<newline count="2"/>
It can be increased to 300 mg/day and 400 mg/day with at least 2 weeks at each dose to achieve steady state at each level</entry>
</row>
</tbody>
</tgroup>
<caption><emphasis effect="bold">Drug Emphasis Table: Other Anticonvulsants</emphasis> (source: https://dailymed.nlm.nih.gov/dailymed/)</caption>
</table>
</section>
</section>
<section id="sect-00018">
<title>Nursing Implications</title>
<para id="para-00053">The nurse should do the following for clients who are taking anticonvulsant drugs:</para>
<list list-type="bulleted" id="list-00010">
<item>Assess the client’s medical history, current drug list, and allergies.</item>
<item>Assess client’s baseline weight and vital signs.</item>
<item>Ensure the drug is prepared appropriately using aseptic technique and verify dosage before administration.</item>
<item>Monitor the client’s response to the drug, including any changes in seizure patterns, neurological condition, and mental status.</item>
<item>Provide client teaching regarding the drug and when to call the health care provider. See below for client teaching guidelines.</item>
</list>
<note class="client-teaching" id="note-00009">
<para id="para-00054"><emphasis effect="bold">The client taking an anticonvulsant drug should:</emphasis></para>
<list list-type="bulleted" id="list-00011">
<item>Take the drug as prescribed and do not skip doses or stop therapy.</item>
<item>Do not use alcohol or smoke—alcohol can depress the central nervous system, and smoking may cause vasoconstriction, resulting in reduced elimination of the drug.</item>
<item>Keep a journal of symptoms and note improved or worsening symptoms.</item>
<item>Take drug with food if gastrointestinal upset occurs.</item>
<item>Have laboratory testing as scheduled by health care provider. Many anticonvulsants require titration and monitoring of blood levels to ensure safety and efficacy.</item>
<item>Report symptoms of dyspnea, confusion, skin rash, abnormal bleeding, and/or infections to health care provider as these may represent an adverse reaction to anticonvulsant drugs.</item>
<item>Speak to their health care provider if they are pregnant or plan to become pregnant before starting these drugs because they can impact the fetus.</item>
<item>Store out of reach children and away from heat, moisture, and light.</item>
</list>
<para id="para-00055"><emphasis effect="bold">The client taking anticonvulsant drugs <emphasis effect="italics">should not</emphasis>:</emphasis></para>
<list list-type="bulleted" id="list-00012">
<item>Drive or operate machinery with central nervous system depressants.</item>
<item>Stop taking the drug unless directed by their health care provider, as this drug class reduces the risk of seizures.</item>
</list>
</note>
</section>
</content>
<glossary>
<definition id="def-00001"><term>absence seizures</term> <meaning>seizures that cause rapid blinking or a few seconds of staring into space, also known as petit mal seizures</meaning></definition>
<definition id="def-00002"><term>anticonvulsant drugs</term> <meaning>drugs that are primarily used to treat seizures and epilepsy</meaning></definition>
<definition id="def-00003"><term>complex focal seizures</term> <meaning>a type of focal seizure that makes a person confused or dazed and unresponsive to questions or directions for up to a few minutes.</meaning></definition>
<definition id="def-00004"><term>computed tomography (CT) scan</term> <meaning>a noninvasive imaging procedure that uses x-rays to produce horizontal and axial images of the brain</meaning></definition>
<definition id="def-00005"><term>convulsions</term> <meaning>an involuntary contraction of muscles that cause sudden irregular movements of the body</meaning></definition>
<definition id="def-00006"><term>electroencephalogram (EEG)</term> <meaning>a test that measures changes in the brain’s electrical patterns that relate to seizures or other neurological conditions</meaning></definition>
<definition id="def-00007"><term>epilepsy</term> <meaning>a neurological disorder characterized by recurrent seizures</meaning></definition>
<definition id="def-00008"><term>focal seizures</term> <meaning>seizures that begin in a specific area of the brain and can cause a wide range of symptoms depending on the area of the brain that is affected; also known as partial seizures</meaning></definition>
<definition id="def-00009"><term>gamma aminobutyric acid (GABA)</term> <meaning>inhibitory neurotransmitter in the central nervous system</meaning></definition>
<definition id="def-00010"><term>generalized seizures</term> <meaning>seizures in which abnormal activity occurs in both sides of the brain from the beginning of the seizure</meaning></definition>
<definition id="def-00011"><term>gingival hyperplasia</term> <meaning>gum overgrowth</meaning></definition>
<definition id="def-00012"><term>grand mal seizures</term> <meaning>seizures that involve both tonic (muscle stiffness) and clonic (muscle jerking) phases, also known as tonic-clonic seizures</meaning></definition>
<definition id="def-00013"><term>idiopathic seizure</term> <meaning>a seizure in which the cause cannot be identified</meaning></definition>
<definition id="def-00014"><term>magnetic resonance imaging (MRI)</term> <meaning>an imaging procedure that uses large magnetic radio waves to produce clear images of the structures inside the skull</meaning></definition>
<definition id="def-00015"><term>partial seizures</term> <meaning>seizures that begin in a specific area of the brain and can cause a wide range of symptoms depending on the area of the brain that is affected; also known as focal seizures</meaning></definition>
<definition id="def-00016"><term>petit mal seizures</term> <meaning>seizures that cause rapid blinking or a few seconds of staring into space; also known as absence seizures</meaning></definition>
<definition id="def-00017"><term>positron emission tomography (PET) scan</term> <meaning>an imaging procedure that uses a radioactive tracer substance to detect disease or injury in the brain</meaning></definition>
<definition id="def-00018"><term>secondary generalized seizures</term> <meaning>seizures that begin in one part of the brain but then spread to both sides of the brain; the person first has a focal seizure, followed by a generalized seizure</meaning></definition>
<definition id="def-00019"><term>seizure</term> <meaning>a sudden and temporary disturbance in the electrical activity of the brain that can cause changes in behavior, movement, or consciousness</meaning></definition>
<definition id="def-00020"><term>simple focal seizures</term> <meaning>seizures that affect a small part of the brain and cause twitching movements or a change in sensation, such as an odd taste or smell</meaning></definition>
<definition id="def-00021"><term>tonic-clonic seizures</term> <meaning>seizures that involve both tonic (muscle stiffness) and clonic (muscle jerking) phases, also known as grand mal seizures</meaning></definition>
</glossary>
</document>